A panel of U.S. health advisers narrowly backed a closely watched COVID-19 pill from Merck. The FDA panel voted 13-10 that the antiviral drug's benefits outweigh its risks, including potential birth defects if used during pregnancy. (Dec. 1)
FDA panel narrowly backs COVID-19 pill from Merck
